[DOI] [PubMed] [Google Scholar] 133.Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM
Given the success of the FLOW trial, Novo Nordisk has said that it has filed for expanded indications for Ozempic to include the prevention of kidney disease progression in patients with type 2 diabetes and CKD in the European Union and expects to hear about the filing sometime this year
Patients now expect at-home administration, simple instructions, minimal pain and less frequent dosing
Advanced formulation designed for precise targeting of localized fat deposits in both facial and body areas
We further demonstrate that slime secretion is necessary for A-motility in M